Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 10, 2024

Osivax and KM Biologics sign deal for influenza vaccine in Japan

France-based biopharmaceutical company Osivax has entered into an exclusive license option agreement with Japanese vaccine manufacturer KM Biologics for a broad-spectrum “universal” influenza vaccine candidates in Japan.

Continue
KM Biologics will carry out the development, manufacturing, and commercialisation of Osivax's vaccine. Credit: CDC on Unsplash.
September 9, 2024

Superluminal Medicines secures $120m in Series A funding round

The company focuses on membrane receptors that facilitate cell signalling and responses critical to human physiology. Credit: Logan Moreno Gutierrez on Unsplash.
September 6, 2024

Moderna’s updated Covid-19 vaccine receives positive EMA CHMP opinion

The EMA CHMP recommendation for the Covid-19 vaccine is grounded in a comprehensive evaluation, including manufacturing and preclinical data. Credit: Mufid Majnun from Pixabay.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

  1. Novartis begins construction works at two RLT manufacturing facilities in US
  2. UK MHRA grants authorisation for Moderna’s updated Covid-19 vaccine
  3. Skyline Therapeutics secures FDA orphan drug status for RP therapy
  4. Novavax’s updated Covid-19 vaccine receives FDA emergency use authorisation
  5. Johnson & Johnson seeks FDA approval for generalised myasthenia gravis therapy

PRESS RELEASES

Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer Remains on Track in First Half of 2024
Gerresheimer Remains on Track in First Half of 2024
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy
RWS’s Linguistic AI Solution Evolve Wins Prestigious 2024 AI Breakthrough Award
RWS’s Linguistic AI Solution Evolve Wins Prestigious 2024 AI Breakthrough Award
Science-Based Targets Initiative Validates RWS’ Commitment to Reducing Carbon Emissions
Science-Based Targets Initiative Validates RWS’ Commitment to Reducing Carbon Emissions

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation